scPharmaceuticals (SCPH) Competitors $3.35 -0.11 (-3.18%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends SCPH vs. CHMA, CMRX, OPTN, FBIO, AQST, TRDA, TECX, ABUS, ANAB, and PHATShould you be buying scPharmaceuticals stock or one of its competitors? The main competitors of scPharmaceuticals include Chiasma (CHMA), Chimerix (CMRX), OptiNose (OPTN), Fortress Biotech (FBIO), Aquestive Therapeutics (AQST), Entrada Therapeutics (TRDA), Tectonic Therapeutic (TECX), Arbutus Biopharma (ABUS), AnaptysBio (ANAB), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "medical" sector. scPharmaceuticals vs. Chiasma Chimerix OptiNose Fortress Biotech Aquestive Therapeutics Entrada Therapeutics Tectonic Therapeutic Arbutus Biopharma AnaptysBio Phathom Pharmaceuticals Chiasma (NASDAQ:CHMA) and scPharmaceuticals (NASDAQ:SCPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk. Does the media refer more to CHMA or SCPH? In the previous week, scPharmaceuticals had 9 more articles in the media than Chiasma. MarketBeat recorded 9 mentions for scPharmaceuticals and 0 mentions for Chiasma. Chiasma's average media sentiment score of 0.46 beat scPharmaceuticals' score of -0.43 indicating that Chiasma is being referred to more favorably in the media. Company Overall Sentiment Chiasma Neutral scPharmaceuticals Neutral Which has more risk and volatility, CHMA or SCPH? Chiasma has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, scPharmaceuticals has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500. Does the MarketBeat Community favor CHMA or SCPH? Chiasma received 93 more outperform votes than scPharmaceuticals when rated by MarketBeat users. However, 66.67% of users gave scPharmaceuticals an outperform vote while only 48.75% of users gave Chiasma an outperform vote. CompanyUnderperformOutperformChiasmaOutperform Votes25348.75% Underperform Votes26651.25% scPharmaceuticalsOutperform Votes16066.67% Underperform Votes8033.33% Do institutionals & insiders believe in CHMA or SCPH? 61.7% of Chiasma shares are held by institutional investors. Comparatively, 89.5% of scPharmaceuticals shares are held by institutional investors. 8.3% of Chiasma shares are held by insiders. Comparatively, 5.5% of scPharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better earnings and valuation, CHMA or SCPH? scPharmaceuticals has higher revenue and earnings than Chiasma. Chiasma is trading at a lower price-to-earnings ratio than scPharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChiasma$1.11M196.11-$74.78M-$1.43-2.63scPharmaceuticals$30.28M5.54-$54.81M-$1.90-1.76 Is CHMA or SCPH more profitable? Chiasma has a net margin of 0.00% compared to scPharmaceuticals' net margin of -264.60%. Chiasma's return on equity of -113.57% beat scPharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ChiasmaN/A -113.57% -57.62% scPharmaceuticals -264.60%-244.93%-68.56% Do analysts recommend CHMA or SCPH? scPharmaceuticals has a consensus price target of $15.00, indicating a potential upside of 347.76%. Given scPharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe scPharmaceuticals is more favorable than Chiasma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chiasma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00scPharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryChiasma and scPharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks. Ad Paradigm Press[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.Click here now for the urgent details on this hidden play. Get scPharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SCPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCPH vs. The Competition Export to ExcelMetricscPharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$167.63M$6.99B$5.38B$8.84BDividend YieldN/A8.15%5.13%4.09%P/E Ratio-1.7610.35102.4617.58Price / Sales5.54362.011,234.85158.43Price / CashN/A52.6040.4736.33Price / Book5.4910.377.096.50Net Income-$54.81M$153.60M$119.65M$226.22M7 Day Performance-3.18%3.92%2.06%3.76%1 Month Performance-23.34%-6.78%-2.46%4.63%1 Year Performance-38.98%33.23%33.95%29.20% scPharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCPHscPharmaceuticals3.8265 of 5 stars$3.35-3.2%$15.00+347.8%-39.0%$167.63M$30.28M-1.7630CHMAChiasmaN/A$3.76flatN/A+0.0%$217.68M$1.11M-2.6385CMRXChimerix4.5282 of 5 stars$0.91+3.4%$8.50+830.3%-6.3%$82.18M$320,000.00-0.9772OPTNOptiNose4.0624 of 5 stars$0.39+5.4%$3.00+669.0%-60.8%$58.84M$70.99M-1.41190FBIOFortress Biotech3.0759 of 5 stars$1.58flat$13.67+767.7%-26.8%$43.34M$62.50M-0.52186Analyst RevisionAQSTAquestive Therapeutics2.2799 of 5 stars$4.56-3.8%$9.80+115.1%+123.5%$415.33M$50.58M-10.52160Positive NewsTRDAEntrada Therapeutics2.5382 of 5 stars$18.05+0.7%$24.00+33.0%+65.5%$675.43M$129.01M11.39110Positive NewsTECXTectonic Therapeutic3.4866 of 5 stars$44.89+2.0%$72.25+60.9%N/A$662.13MN/A-7.62120Analyst ForecastHigh Trading VolumeABUSArbutus Biopharma2.6471 of 5 stars$3.46+0.6%$5.50+59.0%+90.8%$655.64M$18.14M-8.0073Analyst ForecastANABAnaptysBio2.5319 of 5 stars$21.24+4.6%$54.64+157.2%+56.8%$646.44M$17.16M-3.48100PHATPhathom Pharmaceuticals2.628 of 5 stars$9.43+8.0%$22.50+138.7%+33.6%$644.48M$680,000.00-1.66110 Related Companies and Tools Related Companies Chiasma Alternatives Chimerix Alternatives OptiNose Alternatives Fortress Biotech Alternatives Aquestive Therapeutics Alternatives Entrada Therapeutics Alternatives Tectonic Therapeutic Alternatives Arbutus Biopharma Alternatives AnaptysBio Alternatives Phathom Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SCPH) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding scPharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share scPharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SCPH Stock Alerts